Small-Molecule-Driven Hepatocyte Differentiation of Human Pluripotent Stem Cells

Richard Siller,1,4 Sebastian Greenhough,1,4 Elena Naumovska,1 and Gareth J. Sullivan1,2,3,*

1Department of Biochemistry, Faculty of Medicine, Institute of Basic Medical Sciences, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway
2Norwegian Center for Stem Cell Research, PO Box 1112 Blindern, 0317 Oslo, Norway
3Institute of Immunology, Oslo University Hospital-Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway
4Co-first author
*Correspondence: gareth.sullivan@medisin.uio.no
http://dx.doi.org/10.1016/j.stemcr.2015.04.001
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SUMMARY

The differentiation of pluripotent stem cells to hepatocytes is well established, yet current methods suffer from several drawbacks. These include a lack of definition and reproducibility, which in part stems from continued reliance on recombinant growth factors. This has remained a stumbling block for the translation of the technology into industry and the clinic for reasons associated with cost and quality.

We have devised a growth-factor-free protocol that relies on small molecules to differentiate human pluripotent stem cells toward a hepatic phenotype. The procedure can efficiently direct both human embryonic stem cells and induced pluripotent stem cells to hepatocyte-like cells. The final population of cells demonstrates marker expression at the transcriptional and protein levels, as well as key hepatic functions such as serum protein production, glycogen storage, and cytochrome P450 activity.

INTRODUCTION

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) offer a potentially limitless source of cells for industrial and clinical translation, and the ever-advancing field of cellular reprogramming has redefined the limits of cell plasticity (Taylor et al., 2010). Meanwhile, cell culture and production technologies are rapidly improving, and the first instances of pluripotent-cell-derived therapies have entered clinical trials (Schwartz et al., 2012).

Amidst this broadening field, hepatocyte generation is gathering interest with industrial and clinical parties due to its relevance in the areas of drug development, cell therapy, and disease modeling. While the scope of what could be achieved is wide, a number of obstacles remain before human pluripotent stem cell (hPSC) technologies can be adopted for widespread use. On the one hand are the technical challenges relating to scalability, definition, and reproducibility, while from a basic research perspective, many unanswered questions remain regarding the development of an adult phenotype, the mechanisms of cell reprogramming, and the role of the tissue culture microenvironment.

Early protocols for the generation of hepatocytes from pluripotent cells relied on the use of embryoid body formation (Baharvand et al., 2006; Basma et al., 2009; Imamura et al., 2004). This method involves the creation of cell aggregates and the spontaneous differentiation of the pluripotent population to a mixed population of cells representing the three germ layers (Itskovitz-Eldor et al., 2000). Notable improvements in efficiency and functionality have since been achieved by various groups, which based their protocols on developmental signaling and utilized adherent culture conditions. However, all directed differentiation protocols for hepatocyte-like cells (HLCs) published to date have relied on the use of recombinant growth factors such as activin A, Wnt3a, hepatocyte growth factor (HGF), oncostatin M (OSM), fibroblast growth factor 4 (FGF4), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and bone morphogenetic protein 4 (BMP4) (Agarwal et al., 2008; Brolén et al., 2010; Cai et al., 2007; Chen et al., 2012; Hay et al., 2008; Liu et al., 2010; Si-Tayeb et al., 2010b; Song et al., 2009; Sullivan et al., 2010; Touboul et al., 2010).

Some recent progress has been made in replacing growth factors for the differentiation of mesoderm and ectoderm (Chambers et al., 2012; Lian et al., 2012), and efforts have been undertaken to find suitable candidates for the production of definitive endoderm (DE), exemplified by the Melton group, who identified IDE1 and 2 (Borowiak et al., 2009). Recent studies have also demonstrated the utility of other small molecules in priming pluripotent cells for differentiation toward endoderm (Tahamtani et al., 2013) and mesoderm (Tan et al., 2013). To date, however, further endodermal differentiation has only been performed in combination with other recombinant growth factors (for a review, see Han et al., 2012).

A number of publications have demonstrated that Wnt signaling is required to specify DE (Engert et al., 2013; Nakanishi et al., 2009), and we have found that a pulse of GSK-3 inhibition is sufficient to produce...
populations of DE at a high efficiency. We are then able to direct the small-molecule-generated population of DE to functional HLCs with a combination of small molecules, namely DMSO, dexamethasone (DEX), and an HGF receptor agonist N-hexanoic-Tyr, Ile-(6) aminohexanoic amide (dihexa) (McCoy et al., 2013). This stepwise approach is able to generate HLCs at high efficiency, without the inclusion of growth factors (Figure 1). The differentiated cells demonstrate similar levels of function to those derived via published growth-factor-based approaches.

**RESULTS**

**Production of DE Using GSK-3 Inhibition: Phase I**

The ability to produce hepatocytes from hPSCs that have utility in both clinical and research arenas will require methodologies that are robust in terms of efficiency and reproducibility. The majority of methodologies to date are far from this and also reliant on recombinant growth factors to direct cellular fate. This will prove a major hurdle if these cells are to be utilized in a therapeutic environment. We have therefore developed a differentiation approach that allows the production of hepatocyte-like cells from hPSCs with high efficiency, without the inclusion of growth factors.
procedure that is devoid of growth factors and driven by small molecules. The procedure is notionally tri-sected into three phases inducing DE differentiation (phase I), hepatic specification (phase II), and hepatocyte maturation (phase III).

Following studies of the utility of GSK-3 inhibition in priming pluripotent cells for endodermal differentiation (Tahamtani et al., 2013) and reports that Wnt/β-catenin signaling regulates SOX17 expression and is essential for endoderm formation (Engert et al., 2013), we set out to establish whether we could use this approach as a starting point for the generation of functional hepatocytes. We initially established the conditions for DE differentiation in the hESC line H1. Through a 24-hr treatment with 3 μM CHIR99021, followed by 24 hr of non-directed differentiation in RPMI-B27, we were able to guide hPSCs through developmentally relevant stages to produce a population of DE (Figure 2A). Over a 48-hr period, we observed dynamic changes in the gene expression pattern (Figure 3). By 48 hr, we observed elevated expression of DE markers such as FOXA2, GSC, SOX17, HHEX, and CER1 (Ang et al., 1993; Blum et al., 1992; Kanai-Azuma et al., 2002; Monaghan et al., 1993; Sasaki and Hogan, 1993). In addition, early events of the differentiation indicated transition through a primitive streak (PS) intermediate. We observed a rapid upregulation of NODAL within 4 hr of exposure to CHIR99021, which is indicative of a transition toward a PS population (Figure 3) (Lu et al., 2001). This was followed by induction of the PS markers T and GSC (Figure 3). The markers SOX17, GSC, FOXA2, and MIXL1 are expressed in extra-embryonic endodermal lineages as well as DE. In order to demonstrate that our differentiation procedure was not producing primitive endoderm, we examined the levels of SOX7 and observed no upregulation during our procedure (Figure 2A). The observed patterns of expression are similar to those seen with a 3-day treatment of activin A and Wnt3a or a 5-day treatment of activin A (D’Amour et al., 2005; Hay et al., 2008). These changes in gene expression were accompanied by morphological changes; the cells shifted from a pluripotent morphology to dense, bright clusters at 24 hr, followed by a petal-like morphology at 48 hr (Figure 2B). At the 48-hr time point (phase I endpoint), we observed co-expression of FOXA2 and SOX17 at the protein level using immunofluorescence (Figure 2C). We then compared treatments with activin A/Wnt3a, CHIR99021, and vehicle control and found equivalent co-expression of the DE proteins FOXA2 and SOX17 by immunofluorescence in the growth-factor- and small-molecule-treated cells (Figure 2C) and no co-expression in the control (data not shown). Next, we assessed whether GSK-3 inhibition was a generic mechanism to drive hPSCs to DE. Figure 2C demonstrates the utility of an alternative GSK-3 inhibitor (BIO, 1 μM) to produce FOXA2/ SOX17-positive cells under the same conditions, suggesting that GSK-3 inhibition followed by its removal is responsible for commitment to DE. It is well documented that BIO and CHIR99021 are potent pharmacological GSK-3-specific inhibitors that result in activation of the Wnt signaling pathway (Sato et al., 2004; Sineva and Pospolov, 2010), so we next assessed the ability of the protein Wnt3a alone to drive differentiation toward DE. Figure 2C demonstrates that treatment with Wnt3a was sufficient to produce populations of cells that expressed the DE markers FOXA2 and SOX17. This observation indicates that Wnt3a treatment alone can facilitate the production of DE and that the inclusion of activin A is not necessary for DE production in vitro. All treatments described gave similar efficiencies with respect to FOXA2- and SOX17-positive cells: 78%–85% for FOXA2 and 79%–87% for SOX17 (Figure 2D).

**Hepatic Specification through DMSO Treatment of Definitive Endoderm: Phase II**

Following the production of DE through small-molecule stimulation, the next step was to specify a hepatic fate. We explored potential routes to efficiently produce an AFP/HNF4A-positive hepatic progenitor population. There are numerous reports of the utility of small molecule DMSO in stem cell differentiation and specifically in the generation of hepatic progenitors (Hay et al., 2008; Rambhatla et al., 2003; Soto-Gutierrez et al., 2006; Sullivan et al., 2010). Therefore, we used a well-established method consisting of a 5-day treatment with 1% DMSO. On subjecting DE to phase II conditions (DMSO), we observed a rapid change in morphology and a spurt of proliferation. After the 5 days of treatment, we observed 87% co-expression of AFP and HNF4A, as assessed by immunofluorescence (Figures 4A and 4B). This was comparable to activin A/Wnt3a followed by DMSO treatment, in line with previous reports (Figures 4A and 4B). In addition, the cells exhibited typical hepatocyte progenitor morphology as assessed by phase contrast microscopy (Figure 4C). The levels of AFP/HNF4A co-expression observed are indicative that this phase of the differentiation is extremely efficient (Figure 4B). Gene expression was analyzed after the end of hepatic specification by qRT-PCR (Figure 4D), and the panel shows a repertoire of hepatic progenitor markers that were expressed including AFP, CEBPA, FOXA2, GATA4, HNF4A, PROX1, TBX3, and TTR. To assess the differentiation of DE to hepatic progenitors (hepatoblasts), we monitored the gene expression levels of several key developmental markers, which are known to regulate hepatoblast formation in vivo, during the 5-day phase II protocol (Si-Tayeb et al., 2010a). We observed that both small-molecule- and growth-factor-derived DE (hESC line H1) followed a similar trajectory toward hepatic progenitors (Figure 5). During differentiation to hepatic
progenitors, we observed maintenance of FOXA2 levels and an induction of GATA4, both of which are known to be pioneer factors critical to promote the hepatic gene expression program (Kaestner, 2005). Over the 5 days, there was an increase in expression of PROX1 and TBX3, which are believed to interact in vivo to promote the migration and proliferation of hepatoblasts from the primary liver bud (Sosa-Pineda et al., 2000; Lüdtke et al., 2009).

Figure 2. Characterization of Phase I Differentiation: Definitive Endoderm

(A) Gene expression changes during phase I of differentiation as measured by TaqMan qRT-PCR. Blue progression, small-molecule treatment after 24 and 48 hr. Green progression, vehicle control at 24 and 48 hr. Yellow-red progression, published growth-factor-based method (Hay et al., 2008) at 24, 48, and 72 hr. All were performed using H1 hESCs and normalized to ACTB and undifferentiated control. Data are presented as the mean of three independent experiments; error bars represent SD.

(B) Comparison of morphology of growth factor and small-molecule definitive endoderm differentiation at days 0, 1, and 3 for growth factor and days 0, 1, and 2 for small molecule, taken using phase contrast microscopy (10X). Scale bars, 100 μm.

(C) Expression of FOXA2 and SOX17 at phase I endpoint after treatment with activin/Wnt3a, CHIR99021, BIO, or Wnt3a alone, imaged using fluorescent microscopy. The treatment is indicated at the head of each column. Scale bars, 100 μm.

(D) Efficiency of phase I differentiation, determined by counting FOXA2-positive cells and SOX17-positive cells. Efficiencies are presented as the percentage of positive cells plus or minus the SD of all fields counted. See also Figure S2.
Furthermore, we analyzed several key regulators and markers of hepatocyte differentiation and observed strong induction of CEBPA, HNF4A, TTR, and AFP.

Production of HLCs via Dexamethasone and the HGF Receptor Agonist Dihexa: Phase III

The final stage of HLC differentiation (hepatic maturation) has been performed by many groups using a wide range of growth factors such as HGF, OSM, FGF4, VEGF, and EGF (Han et al., 2012). We assessed the literature landscape to find potential small-molecule mimetics of growth factors involved in hepatocyte maturation and identified a potent, stable HGF receptor agonist, N-hexanoic-Tyr, Ile-(6) amino-hexanoic amide (dihexa). This molecule was originally developed as a potential therapeutic intervention for neurodegenerative disorders such as Alzheimer’s disease (McCoy et al., 2013). In addition, we utilized the small-molecule glucocorticoid mimetic dexamethasone (DEX), which is well established in hepatocyte maturation procedures.

We tested a number of base media to establish the optimal concentrations of DEX and dihexa. We initially...
used the proprietary media HepatoZYME (Life Technologies) and established the optimal concentrations of DEX and dihexa as being 100 nM for each (data not shown). However, HepatoZYME is a proprietary reagent and contains the growth factor EGF and thus was unsuitable for this application (Garcia et al., 2001). We next assessed William’s base medium, as this is used in a number of protocols for hepatocyte differentiation. Both DEX and dihexa were required, and the above concentrations gave the best results in terms of morphology and function, but this media was not optimal in our hands (data not shown). We finally settled on a modified formulation of Leibovitz L-15 medium (L-15), which has been described in the literature as a standard method to generate mature hepatocytes (Hay et al., 2008; Sullivan et al., 2010). L-15 medium was supplemented with DEX and dihexa (both at 100 nM), which led to the production of cells displaying typical hepatocyte morphology at the endpoint of the small-molecule-driven differentiation protocol (Figure 6A). The cells were large and angular with bright junctions and in some instances contained multiple nuclei. The resulting HLCs demonstrated expression of the hepatocyte markers albumin (ALB), HNF4A, alpha-1-antitrypsin (A1AT), and AFP by immunofluorescence (Figures 6B–6D). Comparable data can be seen for growth-factor-based differentiation in Figures 6B–6D. We observed comparable efficiencies of differentiation between the growth-factor and small-molecule approaches by assessing ALB/HNF4A, A1AT, and AFP (Figure 6E). To corroborate that the source of the HLCs is from DE rather than from yolk sac, we demonstrated that the DE origin marker CYP7A1 was expressed (Asahina et al., 2004) (Figure 6F). To ensure that the protocol was equivalent to previously described growth-factor-based methods, we produced functional hepatocytes as described by Hay and colleagues (Hay et al., 2008) (see Figures 6B–6D) for validation. Gene expression was analyzed by qRT-PCR (Figure 7A), and the panel shows a repertoire of hepatic markers that were expressed: A1AT (SERPINA1), AFP, ALB, APOA2, ASGR1, CYP3A4, HNF4A, TDO2, and TTR. The observed relative levels of expression were very similar irrespective of being derived via the growth-factor- or small-molecule-based protocol (Figure 7A). We observed similar level of expression with respect to fetal hepatocytes for A1AT (SERPINA1), APOA2, ASGR1, CYP3A4, HNF4A, TDO2, and TTR. However, we observed higher levels of expression of AFP for both small-molecule- and growth-factor-derived HLCs compared to adult and fetal hepatocytes. In all cases, except for AFP, we observed higher levels of expression of all hepatic markers in primary adult hepatocytes.

Small-Molecule-Derived HLCs Demonstrate Hepatic Function

Above, we have shown that small-molecule-derived HLCs (smHLCs) exhibit hepatic morphology and expression of...
hepatocyte-specific markers at the transcriptional and protein levels. We next assessed whether smHLCs displayed functional hepatic characteristics. An important function of hepatocytes is the ability to clear xenobiotics via metabolism through the cytochrome P450 isoenzymes. We assessed smHLCs for their metabolic potential, as compared to growth-factor-derived HLCs. The cytochrome P450 enzymes (CYP) are critical in drug metabolism, in particular CYP1A2 and CYP3A4. We assessed the function of these CYPs in terms of their basal activity and their ability to be induced by rifampicin (CYP3A4) and omeprazole (CYP1A2). We observed higher basal CYP activity in the smHLCs as compared to hESC H1 controls for both CYP1A2 and 3A4 (Figure 7B). On challenge with known inducers of these enzymes, we observed significant induction of both CYPs, to a similar degree as in growth-factor-derived HLCs (Figure 7B). Another key function of hepatocytes is the production of serum proteins, so we examined the ability of the smHLCs to secrete albumin, alpha-1-antitrypsin, and fibronectin by ELISA. All three proteins were

Figure 5. Phase II 5-Day Time Course
The human embryonic stem cell line H1 was differentiated to definitive endoderm using either the small-molecule (blue) or growth-factor (red) protocol. Definitive endoderm was treated with 1% DMSO to differentiate to hepatic progenitors, and cells were collected every 24 hr for 5 days to assess the gene expression of developmentally relevant hepatic markers. Data are presented as the mean of three independent experiments; error bars represent SD. The x axis represents the time (in days) after definitive endoderm. The y axis represents the RQ values from the TaqMan analysis. See also Figure S5.
Figure 6. Characterization of Phase III Differentiation to Hepatocyte-like Cells: Morphology and Immunofluorescence

(A) Morphology of growth-factor and small-molecule protocol endpoints, taken using phase contrast microscopy at 10×. Scale bars, 100 μm.

(B) Expression of albumin and HNF4A at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.

(C) Expression of A1AT at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.

(D) Expression of AFP at protocol endpoint was imaged using fluorescent microscopy. Treatment is indicated at the head of each column. Scale bars, 100 μm.

(legend continued on next page)
detected in the medium at levels similar to those seen from growth-factor-derived cells (Figure 7C). Another function tested was the ability to store glycogen. smHLCs were stained with periodic acid Schiff (PAS) and counterstained with H&E. We observed extensive cytoplasmic staining (pink to purple), indicative of glycogen storage, at levels similar to those observed in growth-factor-derived hepatocytes (Figure 7D). We also examined the uptake of indocyanine green (ICG) in smHLCs; after a brief treatment, ICG-positive cells were clearly visible (Figure 7E).

smHLCs Can Be Derived from Multiple Human Pluripotent Stem Cell Lines

An important attribute of any differentiation methodology is the ability to translate it to other cell lines. This is especially important in the case of hPSCs, as these will provide a basis to model hepatic disease and potentially lead to the development of personalized medicine. In addition, the ability to derive hepatocytes of a defined genotype will be of utility in the areas of toxicology and drug development. To test this, we assessed the potential of a number of hPSC lines. We tested one additional hESC line (207) and three different hiPSC clones derived from the fibroblast line Detroit 551 (RA, RB, and RC), using the conditions applied to the hESC line H1.

Through an initial 24-hr treatment with 3 μM CHIR99021, followed by 24 hr of non-directed differentiation in RPMI-B27, we observed that the differentiation was very inefficient and did not produce the predicted morphology (data not shown) as previously observed for the hESC line H1 (Figure 2B). We next performed a titration of the small molecule CHIR99021 (1–10 μM) in RPMI-B27 ± insulin (Figure S1C). The optimal concentration for CHIR99021 was 4 μM in RPMI-B27 minus insulin in all cases. Over a 48-hr period, we observed dynamic changes in the gene expression pattern (Figure S2A) similar to those previously observed for the hESC line H1. On completion of phase I (48 hr), we observed elevated expression of DE markers such as FOXA2, GSC, SOX17, HHEX, and CER1. These changes in gene expression were accompanied by morphological changes consistent with the hESC line H1 differentiation above (Figure S2B). At the 48-hr time point (phase 1 endpoint), we observed co-expression of FOXA2 and SOX17 at the protein level using immunofluorescence (Figure S2C). All lines gave similar efficiencies with respect to FOXA2- and SOX17-positive cells: 81%–84% for FOXA2 and 79%–82% for SOX17 (Figure S2D). To ensure that hiPSCs were following a developmentally relevant route, we assessed the timing of key events in DE specification. Figure S3 shows induction of the PS markers T, GSC, and NODAL in the first 24 hr. This is followed by specification to definitive endoderm indicated by robust induction of SOX17, GSC, FOXA2, and MIXL1 (Figure S3) and no significant upregulation of SOX7 (Figure S2A).

On confirmation of DE specification, we next sought to specify a hepatic fate. We utilized the same phase II conditions (DMSO) as described above. After the 5 days of treatment, we observed a rapid change in morphology, accompanied with proliferation. For all lines tested, we observed typical hepatic progenitor morphology as assessed by phase contrast microscopy (Figure S4A). We observed efficiencies of between 86% and 89% based on AFP/HNF4A co-expression, as assessed by immunofluorescence (Figures S4B and S4C). Gene expression was analyzed after the end of hepatic specification by qRT-PCR, at which point we observed equivalent expression profiles as hESC H1 (Figure S4D). In addition, as with the hESC line H1, we performed a time course over 5 days and observed a very similar developmental marker profile (Figure S5). The validated hepatic progenitor cells from the different hPSCs were then subjected to phase III differentiation (Figures 1C and S1C). On completion of the differentiation, all lines efficiently generated smHLCs as assessed by morphology (Figure S6A). All lines demonstrated extensive expression of ALB/ HNF4A and alpha-1-antitrypsin by immunofluorescence (Figures S6B and S6C). Both hESC line 207 and hiPSC-derived smHLCs secreted albumin, alpha-1-antitrypsin, and fibronectin as assessed by ELISA. All three proteins were detected in the medium at levels similar to those observed for H1 (Figures S7A). We demonstrated that the hiPSC-derived smHLCs were from a DE origin via the presence of CYP7A1 (Figure S7B). We observed comparable efficiency of smHLC production to hESC H1 (between 72% and 79% for ALB/HNF4A and between 88% and 92% for A1AT; Figure S7C). Finally, we assessed the expression levels of the following hepatocyte markers: A1AT (SERPINA1), AFP, ALB, APOA2, ASGR1, CYP3A4, HNF4A, TDO2, and TTR by qRT-PCR, and profiles very similar to H1-derived smHLCs were observed (Figure S7C). Thus, we demonstrated that our protocol was applicable to other hESC and hiPSC lines.
DISCUSSION

We have developed a protocol for the efficient differentiation of functional HLCs from hPSCs that does not require the addition of recombinant growth factors and is applicable to both hESCs and hiPSCs. During the development of the protocol, it came as a surprise to discover that pluripotent cells can be differentiated to DE with a short pulse (24 hr) of CHIR99021, BIO, or Wnt3a without the inclusion of activin A. The rationale to examine GSK-3...
inhibition as a route to producing DE has a basis in the observations of Lickert and colleagues (Engert et al., 2013), who demonstrated that Wnt signaling regulates SOX17 expression. A number of other publications also describe the priming activity of GSK-3 inhibitors such as CHIR99021 (Hannan et al., 2013; Kunisada et al., 2012; Tahamtani et al., 2013; Tan et al., 2013). In this study, we clearly demonstrate that GSK-3 inhibition alone is sufficient to produce DE, a finding that in itself represents an opportunity for major saving in hepatocyte-production costs. Importantly, this first stage provided productive DE, which expressed a battery of DE markers including SOX17 and FOXA2, and passed through the equivalent developmental points as growth factor DE (Figure 2A). The use of DMSO to drive DE toward a hepatic fate is well established in the field (Hay et al., 2008; Soto-Gutiérrez et al., 2007; Sullivan et al., 2010), and we show here that it is equally successful when employed following CHIR99021 treatment as with activin A and Wnt3a. We observed a rapid change in morphology, coupled with the appearance of the hepatic progenitor markers HNF4A and AFP, both at the transcriptional and protein levels. The final phase of this protocol was to take hepatic progenitors and provide the environment for hepatocyte maturation in order to generate HLCs. We chose to utilize a combination of two small molecules of the glucocorticoid family, DEX and hydrocortisone-21-hemisuccinate (HC), and assessed the literature for potential mimetics of commonly used growth factors. We identified a potent HGF mimetic called N-hexanoic-Tyr, Ile-(6) aminohexanoic amide, or dihexa, originally developed as an anti-dementia drug (McCoy et al., 2013). This molecule was identified in a screen that assessed the capacity to potentiate the biological activity of HGF. We therefore employed the small molecules DEX, HC and dihexa in phase III of the protocol. Initially, phase III was optimized using the commercially available base medium HepatoZYME that has been shown to provide supportive conditions for hepatocyte maturation (Szkolnicka et al., 2014). We demonstrated the dependency of dihexa in this system (data not shown), but it transpired that HepatoZYME is not growth factor free and contains the morphogen EGF (Garcia et al., 2001). We then translated our findings to the routinely used hepatocyte maturation medium L-15, which others have used supplemented with a combination of growth factors and small molecules (Hay et al., 2008; Sullivan et al., 2010). We supplemented L-15 with the aforementioned small molecules and efficiently generated HLCs from both hESCs and hiPSCs, which displayed typical hepatic morphology and expressed a number of hepatic markers at the transcriptional and protein levels. More importantly, the smHLCs exhibited key functional attributes including serum protein production and cytochrome P450 metabolism. It should be stated that we used the P450-Glo assay system (Promega) to initially assess function with respect to CYP activity as in line with many other publications. But, in order to gain a thorough insight into the metabolic potential of these cells, we will need to assess them using the more robust and accepted methods including mass spectrometry and high-performance liquid chromatography. It should be noted that the above method is not fully defined at this point, as the present L-15 formulation contains 8.3% serum. We are currently investigating avenues to generate a completely defined system for the production of hepatocytes, but the method described here represents a significant step toward this goal and is applicable to both hESC and hiPSC lines. Importantly, it provides a means to cut the costs associated with hepatocyte production. A combination of this small-molecule approach with the steadily advancing field of cell-culture automation may eventually allow for the production of high-quality hepatocytes from stem cells at large scale for industrial and clinical translation. In the meantime, this approach in our hands produces cells of equivalent phenotype and function to current approaches and addresses some of the cost, quality, and supply-chain concerns associated with reliance on recombinant growth factors.

In conclusion, we demonstrate here the efficient generation of both hESC- and hiPSC-derived HLCs through the use of small molecules, removing the longstanding reliance on recombinant growth factors. This may go on to provide the foundations for scalable hepatocyte production for use in disease modeling, cell therapy, drug discovery, and basic research in terms of improving maturity and function in vitro.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**

H1 hESCs (WiCell) and 207 hESCs (Ström et al., 2010) and Detroit 551 (ATCC CCL-110) hiPSCs were maintained at 37°C/5% CO2 in feeder-free conditions using growth-factor-reduced Matrigel (Sigma-Aldrich) and E8 Medium (Life Technologies), with routine passaging performed at a 1:3 ratio using 0.5 mM EDTA (Life Technologies). All Matrigel plates were coated with a 1:48 dilution in Advanced DMEM-F12 (Life Technologies) and incubated at 37°C/5% CO2 for 1 hr prior to use.

**Hepatocyte Differentiation**

Cells were seeded onto Matrigel-coated 12-well plates in E8 medium at a 1:3–1:4 split ratio and allowed to adhere for 24 hr at 37°C/5% CO2. It should be noted that the optimal cell density for each line needs to be established. The cells were washed with PBS before being treated with differentiation media. The differentiation protocol utilizes a base media similar to a well-established differentiation protocol (Hay et al., 2008), with replacement of...
all growth factors with small molecules and minor adjustments in timing. The protocol incorporates several stages (Figure 1) utilizing different small molecules. Phase I of differentiation consists of a 24-hr treatment with RPMI-B27 ± insulin (RPMI 1640 GlutaMAX + B27 supplement, both from Life Technologies) plus 3–4 μM CHIR99021 (Stemgent), followed by a 24-hr treatment with RPMI-B27 alone. Phase II consists of 5 days of treatment with knockout DMEM containing 20% knockout serum replacement, 2 mM GlutaMAX, 100 μM 2-mercaptoethanol, 1× MEM non-essential amino acids (Life Technologies), and 1% DMSO (Sigma-Aldrich). Phase III consists of 10 days of treatment with Leibovitz L-15 media containing 8.3% tryptose phosphate broth, 10 μM hydrocortisone 21-hemisuccinate, 50 μg/ml sodium-L-ascorbate, 100 mM dexamethasone (all from Sigma-Aldrich), 0.58% insulin-transferrin-selenium (ITS), 2 mM GlutaMAX (all from Life Technologies), 8.3% fetal bovine serum (Lonza), and 100 nM dihexa ferrin-selenium (ITS), 2 mM GlutaMAX (all from Life Technologies), and 1% DMSO (Sigma-Aldrich). Phase III consists of 10 days of treatment with Leibovitz L-15 media containing 20% knockout serum replacement, 2 mM GlutaMAX, 100 μM 2-mercaptoethanol, 1× MEM non-essential amino acids (Life Technologies), and 1% DMSO (Sigma-Aldrich). During phases II and III, cells are fed every 48 hr. Cells were photographed during differentiation using a Zeiss phase contrast microscope and ZEN software. The scale bars represent 100 μm. Control H1 hESCs (growth factor) were differentiated using activin A, Wnt3a, DMSO, OSM, and HGF (Peprotech) as described previously (Hay et al., 2008; Sullivan et al., 2010). All small molecules were made up in DMSO; vehicle control differentiations were performed using equivalent concentrations.

Small Molecules
For a complete list of small molecules, sources, and purity, please see Table S4. Detailed methods are described in the Supplemental Experimental Procedures.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and four tables and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2015.04.001.

AUTHOR CONTRIBUTIONS
S.G. and R.S. contributed equally to this work. S.G., R.S., and G.J.S. were all extensively involved in designing, performing, and analyzing the experiments. E.N. was involved in data acquisition and analysis. S.G., R.S., and G.J.S. wrote and revised the paper.

ACKNOWLEDGMENTS
We would like to thank Prof. Joseph Harding for the gift of dihexa. This paper will form the basis of a patent application on which S.G. and G.J.S. are named as inventors.

Received: April 16, 2014
Revised: April 2, 2015
Accepted: April 2, 2015
Published: April 30, 2015

REFERENCES


